The Globalย Cancer Monoclonal Antibodies Marketย size was valued at $55.6 billion in 2021, and is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031.
Cancer monoclonal antibodies (mAbs) are a type of immunotherapy that target cancer cells by binding to specific proteins on their surface. They are used for the treatment of various types of cancer, including breast cancer, lung cancer, and lymphoma. The global cancer monoclonal antibodies market is expected to grow significantly in the coming years, driven by the increasing prevalence of cancer, the rise in research and development activities, and the increasing demand for targeted therapies.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/32341
By type, the market is segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. The conjugated monoclonal antibodies segment is expected to hold the largest market share due to the increasing use of antibody-drug conjugates (ADCs) for cancer treatment.
By end-user, the market is segmented into hospitals, clinics, and others. The hospitals segment is expected to hold the largest market share due to the availability of advanced healthcare infrastructure and the increasing demand for innovative cancer therapies.
North America is expected to dominate the cancer monoclonal antibodies market due to the presence of a large number of pharmaceutical companies, high R&D investment, and supportive government initiatives. Europe and Asia-Pacific are also expected to witness significant growth during the forecast period.
๐๐ก๐๐ญ ๐ข๐ฌ ๐ญ๐ก๐ ๐๐ฆ๐ฉ๐๐๐ญ ๐จ๐ ๐๐จ๐ฏ๐ข๐-๐๐ ๐๐๐ง๐๐๐ฆ๐ข๐ ๐จ๐ง ๐๐๐ง๐๐๐ซ ๐๐จ๐ง๐จ๐๐ฅ๐จ๐ง๐๐ฅ ๐๐ง๐ญ๐ข๐๐จ๐๐ข๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ฅ๐จ๐๐๐ฅ๐ฅ๐ฒ?
The outbreak of the COVID-19 pandemic had a negative impact on the cancer monoclonal antibodies market as the hospitalization rate for infected patients increased and the scope of hospitalization for patients for surgeries reduced significantly.
Due to the increase in hospitalization of Covid-19 patients, healthcare professionals postponed cancer treatments as patients with cancer have low immunity and there are high chances that they may catch infection quickly. Hence, the focus shifted to the management and control of the COVID-19 patients. Therefore, there was a reduction in cancer diagnosis cases during the pandemic, leading to a decline in demand for cancer monoclonal antibody testing.
The market has gained momentum with life getting back to normal.
๐๐ซ๐จ๐๐ฎ๐ซ๐ ๐๐จ๐ฆ๐ฉ๐ฅ๐๐ญ๐ ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐ ๐๐๐ ๐๐ฌ ๐๐๐ ๐ฐ๐ข๐ญ๐ก ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ, ๐๐ก๐๐ซ๐ญ๐ฌ, ๐๐๐๐ฅ๐๐ฌ,๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ) https://www.alliedmarketresearch.com/checkout-final/fd3b82369f90375987256ab96c54d8eb
The report offers a detailed segmentation of the global cancer monoclonal antibodies market based on antibody type, application, end user, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.
In terms of antibody type, the humanized segment captured the largest market share of two-fifths of the global cancer monoclonal antibodies market in 2021 and is expected to maintain a prominent revenue growth in 2031. The same segment is expected to achieve the fastest CAGR of 7.1% through 2031. The report also discusses the murine and chimeric segments.
In terms of application, the blood cancer segment captured the largest market share of more than one-third of the global cancer monoclonal antibodies market in 2021 and is likely to dominate the market in 2031. However, the lung cancer segment is expected to dominate in terms of revenue and achieve the fastest CAGR of 7.3% through 2031. The report also offers an analysis of breast cancer and others segments.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ- https://www.alliedmarketresearch.com/purchase-enquiry/32341
Based on end user, the hospitals and clinics segment held the largest share in 2021, accounting for nearly three-fourths of the global cancer monoclonal antibodies market and would maintain its dominance through 2031. Moreover, the same segment is estimated to witness the fastest CAGR of 7.1% during the forecast period. The study also includes an analysis of the research and academic institute/laboratories segment.
Based on region, the market in North America was the largest in 2021, accounting for more than two-fifths of the global cancer monoclonal antibodies market in 2021 and is expected to rule the roost during the forecast period. However, the market in Asia-Pacific is expected to manifest the highest CAGR of 7.5% from 2022 to 2031. The other regions analyzed in the study include LAMEA and Europe.
๐๐๐๐๐ข๐ง๐ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐จ๐ ๐ญ๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐๐๐ง๐๐๐ซ ๐ฆ๐จ๐ง๐จ๐๐ฅ๐จ๐ง๐๐ฅ ๐๐ง๐ญ๐ข๐๐จ๐๐ข๐๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ ๐๐ง๐๐ฅ๐ฒ๐ณ๐๐ ๐ข๐ง ๐ญ๐ก๐ ๐ซ๐๐ฌ๐๐๐ซ๐๐ก ๐ข๐ง๐๐ฅ๐ฎ๐๐,
Roche Holdings Ltd.
Johnson & Johnson
Pfizer Inc.
Novartis AG
AstraZeneca plc
Merck & Co. Inc.
Celgene Limited
Bistrol-Myers Squibb
Eli Lilly & Co.
Abbvie Inc.
๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐ข๐ง ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ:
Infertility Treatment Market Share : https://www.alliedmarketresearch.com/infertility-treatment-market-A09505
Branded Generics Market Size : https://www.alliedmarketresearch.com/branded-generics-market-A10537
๐๐จ๐ง๐ญ๐๐๐ญ:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.
Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.